Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $4.7 million.

  • Outlook Therapeutics' Accumulated Expenses rose 3900.63% to $4.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.7 million, marking a year-over-year increase of 3900.63%. This contributed to the annual value of $5.3 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Outlook Therapeutics' Accumulated Expenses is $4.7 million, which was up 3900.63% from $5.3 million recorded in Q3 2025.
  • Over the past 5 years, Outlook Therapeutics' Accumulated Expenses peaked at $5.3 million during Q3 2025, and registered a low of $3.1 million during Q1 2025.